In one matched cohort of 300 patients, yes. Symptomatic remission at twelve weeks was 66.7% on a GLP-1 against 25.3% without one [1]. The adjusted odds ratio was 5.90 (95% CI 3.52 to 9.86). That is 150 pairs at one center, with nobody randomized. A separate cohort of 9,766 matched pairs with Crohn’s disease put one-year hospitalization at 10.0% against 24.7% [2]. Neither study makes a GLP-1 a treatment for inflammatory bowel disease, and neither set of authors says it does.
This drug slows the gut. Ulcerative colitis is measured partly by how often a patient goes to the bathroom. The improvement in that measure was very large. The first question is whether the measure moved or the disease did. That is the question every endpoint choice forces.
What was found in ulcerative colitis
The study covered one academic health system. Adults with ulcerative colitis who started liraglutide or semaglutide, and stayed on it at least 12 weeks, were eligible. They were started for metabolic reasons, not for the colitis. Each was matched one to one against a patient with the condition who did not. Symptomatic remission was 34.7% against 15.3% at four weeks, 54.7% against 18.0% at eight, and 66.7% against 25.3% at twelve. Mean partial Mayo scores fell from 5.8 at baseline to 2.1, against 4.6 in controls.
Semaglutide did better than liraglutide, 72.5% against 60%, odds ratio 1.77, p=0.04. Weight loss was not associated with remission.
The obvious objection
Partial Mayo is a symptom score. Two of its components are stool frequency and rectal bleeding. These drugs slow gastric emptying and intestinal transit as their central mechanism. A person going less often scores lower on a scale that counts how often they go. Nothing need have changed in the colon.
What the Crohn’s cohort adds
The second study drew on 162 organizations and matched 9,766 pairs on more than thirty covariates [2]. Hospitalization at one year was 10.0% against 24.7% (RR 0.40, 95% CI 0.38–0.43). Emergency visits were 18.9% against 25.3% (RR 0.75, 95% CI 0.71–0.79). Both associations held at five years.
The most informative number is the one that did not move. Corticosteroid use at one year was the same in both arms, RR 1.00, 95% CI 0.96 to 1.03. A healthy-user effect driving everything should have dragged that outcome too. It did not. The full reading of that cohort, including a mortality figure its own authors disown, is in the Crohn’s cohort.
What still deserves suspicion
An adjusted odds ratio of 5.90 is very large. Effect sizes that size in matched observational data usually shrink when somebody randomizes. The reasons are familiar. People prescribed a new drug for metabolic reasons differ from people not prescribed one. Records do not capture those differences, including how closely a patient’s gastroenterology is managed. That is the limit every matched-records study runs into, and it does not shrink because the result is interesting.
One hundred and fifty pairs at one tertiary center over two years is also a small, particular population. Everyone in it was well enough and metabolically unwell enough to be started on a GLP-1.
The finding that cuts the other way
Weight loss was not associated with remission. If the benefit were the downstream effect of losing weight, the people who lost most should have improved most. They did not.
That points toward something more direct. GLP-1 receptors are present in the gut and these drugs have measurable anti-inflammatory effects. It is also the kind of mechanistic inference that a study without randomization can support only weakly, however sensible it sounds.
The motility caution, and how strong it is
Inflammatory bowel disease is often cited as a reason for caution with a drug that slows the gut. The evidence behind that caution is thinner than the warnings suggest. A systematic review of GLP-1-induced gastroparesis found thirteen published cases in total [3]. A separate real-world analysis of patients with irritable bowel syndrome found fewer gastrointestinal events on the drug, not more [4]. Both are set out in the gastroparesis evidence.
What this means for a reader
Nothing to buy. No seller on this roster offers anything for ulcerative colitis, and none claims it. Nobody should start a GLP-1 for inflammatory bowel disease on one matched cohort.
What it is worth is a conversation. Someone with ulcerative colitis who is considering one of these drugs for weight has a reason to raise it. The place to raise it is a gastroenterologist, not an intake form. Inflammatory bowel disease is exactly the kind of history a telehealth questionnaire may never ask about.